Karissa Hammer

Dr. Karissa Hammer

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2022 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
KHKarissa Hammer
Karissa Hammer
VJVictoria S. Jiang
Victoria S. Jiang
MKManoj Kumar Kanakasabapathy
Manoj Kumar Kanakasabapathy
PTPrudhvi Thirumalaraju
Prudhvi Thirumalaraju
HKHemanth Kandula
Hemanth Kandula
HSHadi Shafiee
Hadi Shafiee

4 March 2020 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
ZPZ. Pavlovic
Z. Pavlovic
KHKarissa Hammer
Karissa Hammer
MRM. Raff
M. Raff
PPP. Patel
P. Patel
KKK. N. Kunze
K. N. Kunze
JHJ. Hirshfeld-Cytron
J. Hirshfeld-Cytron

7 November 2022 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
CGCatherine E. Gordon
Catherine E. Gordon
KHKarissa Hammer
Karissa Hammer
KJKaitlyn James
Kaitlyn James
ALAndrea Lanes
Andrea Lanes
SVStylianos Vagios
Stylianos Vagios
ISIrene Souter
Irene Souter

1 April 2020 in Fertility and Sterility
Verified
Journal Article
Closed access
KHKarissa Hammer
Karissa Hammer
SVStylianos Vagios
Stylianos Vagios
CSCaitlin Sacha
Caitlin Sacha
JHJ.Y. Hsu
J.Y. Hsu
CBC.L. Bormann
C.L. Bormann
ISI. Souter
I. Souter

1 September 2020 in Fertility and Sterility
Verified
Journal Article
Closed access
SVStylianos Vagios
Stylianos Vagios
KHKarissa Hammer
Karissa Hammer
CSCaitlin Sacha
Caitlin Sacha
IDIrene Dimitriadis
Irene Dimitriadis
CBCharles L. Bormann
Charles L. Bormann
ISIrene Souter
Irene Souter

6 August 2021 in Human Reproduction
Verified
Journal Article
Open access
PDF file
SVStylianos Vagios
Stylianos Vagios
CSCaitlin Sacha
Caitlin Sacha
KHKarissa Hammer
Karissa Hammer
VFV W Fitz
V W Fitz
IDI Dimitriadis
I Dimitriadis
CBC L Bormann
C L Bormann
How have the coronavirus 2019 (COVID–19)-driven changes in semen collection protocols, from on-site to at-home collection, impacted intrauterine insemination (IUI) cycle outcomes? Our data suggest that at-home semen collection within 2 hours of processing does not negatively impact semen parameters and IUI pregnancy outcomes. What is known already: There are mixed reports regarding the effect of at-home semen collection on IUI outcomes. In a study of 633 cycles, no differences in semen parameters or pregnancy rates were observed between home and clinic collections1. Conversely, in a smaller cohort, at-home collection was associated with worse pregnancy outcomes when IUI was coupled with gonadotropin stimulation, but not when coupled with clomiphene2. We previously reported no differences in semen parameters and in-vitro fertilization (IVF) embryo transfer outcomes, when cycles using semen collected at-home were compared to cycles with on-site collection3. However, such findings cannot necessarily be extended to the IUI setting. This is a retrospective cohort study of all 529 IUI cycles that took place in 2020 at an academic fertility center. Semen collected at the “clinic” was used for 143 cycles before the COVID–19 pandemic, and “at-home” collected specimens were used for the 386 cycles following the revised semen collection protocol. Participants/materials, setting, methods: Prior to the COVID–19 pandemic, semen was collected at our “clinic” and processed within ∼30 minutes. Post-COVID, in order to maintain social distancing, semen was collected “at-home”, at an IUI-approved cup, and transported to our center within 2 hours, while maintained to room temperature. Logistic regression models were performed to evaluate the effect of “at-home” collection on achieving pregnancy (positive pregnancy test-PPT) and clinical pregnancy (sonographic confirmation-CP), adjusting for age and anti-Mullerian hormone (AMH). The mean age (SD) (years) of the female partner was 35.4 (4.2) vs. 35.4 (4.4) (p = 0.978) and of the male partner 36.6 (4.4) vs. 37.1 (p = 0.328) for the “clinic” vs. “at-home” groups, respectively. There were no significant differences in day–3 follicle stimulating hormone and AMH. In both groups the most common diagnoses were idiopathic and combined factors infertility (27.3% and 18.9% & 24.1% and 25.1%, respectively for the “clinic” & “at-home” groups, p = 0.376). Similarly, there were no differences regarding ovarian stimulation, and gonadotropins were the most common medication used in both groups (“clinic”: 44.1% vs. “at-home”: 39.4%, p = 0.775). Semen analysis parameters (volume, motility, forward progression, total motile count) were comparable between the 2 groups, with the exception of concentration (mil/ml) which was higher with “at-home” collection [66.1 (45.0) vs. 81.1 (63.0), p = 0.009]. In unadjusted models, “at-home” collection had no significant effect on the odds for a PPT [OR (95%CI): 0.691 (0.427–1.119), p = 0.133] or CP [0.751 (0.447–1.263), p = 0.281]. These results persisted even when adjusting for maternal age and AMH: PPT [0.708 (0.435–1.153), p = 0.165] and CP [0.773 (0.455–1.312), p = 0.340]. When sub-analysis was performed within the different medication groups, the above findings persisted for both gonadotropin and oral medication cycles. The limitations of the study include its retrospective design and the absence of livebirth data, given the limited follow up period. However, regarding the latter, one can use the ongoing clinical pregnancy rate as an accurate estimate of livebirth. Wider implications of the findings: At-home semen collection within 2 hours of processing did not negatively impact semen analysis parameters or pregnancy outcomes following IUI. These data constitute an important addition to the current limited literature on the subject and provides an additional level of safety for our patients and staff during the COVID–19 crisis. Not applicable